Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275


To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective Experience.

Kullmann T, Gauthier H, Serrate C, Pouessel D, le Maignan C, Misset JL, Culine S.

Pathol Oncol Res. 2017 Jan;23(1):139-144. doi: 10.1007/s12253-016-0111-4. Epub 2016 Sep 7.


A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.

Gunzer K, Joly F, Ferrero JM, Gligorov J, de Mont-Serrat H, Uttenreuther-Fischer M, Pelling K, Wind S, Bousquet G, Misset JL.

Springerplus. 2016 Jan 19;5:45. doi: 10.1186/s40064-015-1601-7. eCollection 2016.


Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM; Francilian Breast Intergroup.

Oncologist. 2015 Aug;20(8):873-9. doi: 10.1634/theoncologist.2014-0467. Epub 2015 Jun 25.


¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.

Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL.

Eur J Radiol. 2014 Oct;83(10):1925-33. doi: 10.1016/j.ejrad.2014.05.037. Epub 2014 Jun 17.


[History of medical oncology].

Misset JL.

Bull Cancer. 2013 May;100(5):403-6. French. No abstract available.


Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schoffski P, Misset JL.

Br J Cancer. 2012 Jul 24;107(3):435-41. doi: 10.1038/bjc.2012.286. Epub 2012 Jul 5.


[Melanoma during pregnancy].

Pagès C, Misset JL, de Kerviler E, Bavoux F, Fernandez H, Viguier M.

Ann Dermatol Venereol. 2012 Apr;139(4):298-304; quiz 296-7, 306-7. doi: 10.1016/j.annder.2012.01.011. Epub 2012 Mar 2. Review. French. No abstract available.


Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

Bousquet G, Alexandre J, Le Tourneau C, Goldwasser F, Faivre S, de Mont-Serrat H, Kaiser R, Misset JL, Raymond E.

Br J Cancer. 2011 Nov 22;105(11):1640-5. doi: 10.1038/bjc.2011.440. Epub 2011 Oct 25.


The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.

Groheux D, Giacchetti S, Espié M, Vercellino L, Hamy AS, Delord M, Berenger N, Toubert ME, Misset JL, Hindié E.

J Nucl Med. 2011 Oct;52(10):1526-34. doi: 10.2967/jnumed.111.093864. Epub 2011 Aug 30.


[Node negative breast cancer. Beyond international consensus: a pragmatic approach].

Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M.

Bull Cancer. 2011 Jul;98(7):807-25. doi: 10.1684/bdc.2011.1395. French.


A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Le Cesne A, Yovine A, Blay JY, Delaloge S, Maki RG, Misset JL, Frontelo P, Nieto A, Jiao JJ, Demetri GD.

Invest New Drugs. 2012 Jun;30(3):1193-202. doi: 10.1007/s10637-011-9662-0. Epub 2011 Apr 12.


[Evaluating the benefits of mammographic breast cancer screening].

Kullmann T, Misset JL.

Orv Hetil. 2010 Aug 29;151(35):1409-14. doi: 10.1556/OH.2010.28864. Hungarian.


Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M.

Oncologist. 2010;15(8):799-809. doi: 10.1634/theoncologist.2009-0029. Epub 2010 Jul 29.


Optimization of cisplatin doses in a testicular cancer patient with acute renal failure.

Pouliquen AL, Bousquet G, Le Maignan C, Bauer C, Lejri N, Misset JL, Lokiec F.

J Oncol Pharm Pract. 2011 Sep;17(3):265-9. doi: 10.1177/1078155209351761. Epub 2009 Nov 19.


[PET/CT in breast cancer: an update].

Groheux D, Moretti JL, Giacchetti S, Hindié E, Teyton P, Cuvier C, Bousquet G, Misset JL, Boin C, Espié M.

Bull Cancer. 2009 Nov;96(11):1053-70. doi: 10.1684/bdc.2009.0950. Review. French.


[Sentinel node biopsy in breast cancer].

Hindié E, Groheux D, Espie M, Bourstyn E, Toubert ME, Sarandi F, de Roquancourt A, Giacchetti S, Cuvier C, Cahen-Doidy L, Teyton P, Misset JL, Maylin C, Moretti JL.

Bull Cancer. 2009 Jun;96(6):713-25. doi: 10.1684/bdc.2009.0879. French.


[Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors].

Oudard S, Quoix E, Jenabian A, Bergougnoux L, Chouahnia K, Ferrero JM, Misset JL, Spaëth D.

Therapie. 2009 Jan-Feb;64(1):17-25. doi: 10.2515/therapie/2009002. Epub 2009 May 26. French.


Should FDG PET/CT be used for the initial staging of breast cancer?

Groheux D, Hindié E, Rubello D, Espié M, Baillet G, Giacchetti S, Misset JL, Moretti JL.

Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1539-42. doi: 10.1007/s00259-009-1159-0. Review. No abstract available.


[Advantages of PET-CT in the work-up of cervical cancer].

Groheux D, Hindie E, Baillet G, Hennequin C, Misset JL, Sarandi F, Toubert ME, Barre E, Moretti JL.

Bull Cancer. 2009 Feb;96(2):199-211. doi: 10.1684/bdc.2008.0815. Review. French.


18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.

Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindié E, Moretti JL.

Cancer Biother Radiopharm. 2009 Feb;24(1):137-44. doi: 10.1089/cbr.2008.0527.


2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer.

Marec-Berard P, Chastagner P, Kassab-Chahmi D, Casadevall N, Marchal C, Misset JL, Ray-Coquard I.

Pediatr Blood Cancer. 2009 Jul;53(1):7-12. doi: 10.1002/pbc.21953. Review.


[Lung cancers in the elderly].

Trédaniel J, Savinelli F, Sergent G, Bousquet G, Le Maignan C, Hennequin C, Gossot D, Misset JL.

Bull Cancer. 2008 May 28;95 FMC Onco:F57-64. doi: 10.1684/bdc.2007.0536. French.


[Decision making process in oncology: rationale and delineation of a composite index of relative antitumoral efficacy (In-RATE)].

Marty M, Blay JY, Trédaniel J, Koscielny S, Hagège C, Asselain B, Goldwasser F, Misset JL.

Bull Cancer. 2008 Nov;95(11):1075-82. doi: 10.1684/bdc.2008.0738. French.


[Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)].

Marchal C, Misset JL, Casadevall N, Marec-Bérard P, Chastagner P, Kassab-Chahmi D, Ray-Coquard I; National French Federation of Comprehensive Cancer Centres.

Cancer Radiother. 2008 Mar;12(2):126-33. French.


[Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)].

Ray-Coquard I, Kassab-Chahmi D, Casadevall N, Chastagner P, Marchal C, Marec-Bérard P, Misset JL; Standards, Options et Recommandations (SOR); Institut National du Cancer; Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC); Ligue contre le Cancer pour la Vie; Fédération Hospitalière de France; Fédération Nationale de Cancérologiedes Centres Hospitaliers Regionaux et Universitaires (FNCHRU); Fédération Française de Cancérologie; Union Nationale Hospitalière Privée de Cancérologie (UNHPC).

Bull Cancer. 2008 Apr;95(4):433-41. doi: 10.1684/bdc.2008.0635. Review. French.


Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, Hennequin C, Vilcoq JR, Cuvier C, Toubert ME, Filmont JE, Sarandi F, Misset JL.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):695-704. doi: 10.1016/j.ijrobp.2008.02.056. Epub 2008 Apr 23.


What is an "elderly" oncologic patient?

Misset JL, Bauer C.

Crit Rev Oncol Hematol. 2008 Jul;67(1):62-3. doi: 10.1016/j.critrevonc.2008.02.001. Epub 2008 Mar 21. No abstract available.


[Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment].

Lhommé C, Planchamp F, Joly F, Leblanc E, Albin N, Alliot C, Auclerc G, Cappiello M, Chaigneau L, Delva R, Dohollou N, Guillemet C, Misset JL, Ray-Coquard I, Rhliouch H, Touboul E, Tournigand C; groupe de travail SOR.

Bull Cancer. 2007 Dec;94(12):1093-106. Review. French. No abstract available.


Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.

Varna M, Soliman H, Feugeas JP, Turpin E, Chapelin D, Legrès L, Plassa LF, de Roquancourt A, Espié M, Misset JL, Janin A, de Thé H, Bertheau P.

Br J Cancer. 2007 Oct 22;97(8):1157-64. Epub 2007 Sep 18.


[Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].

Fagnani F, Colin X, Arveux P, Coudert B, Misset JL.

Bull Cancer. 2007 Jul;94(7):711-20. French.


[Interests and perspectives of PET-CT for breast cancer: review of the literature].

Groheux D, Hindie E, Espié M, Toubert ME, Misset JL, Giacchetti S, Vercellino L, Moretti JL.

Bull Cancer. 2007 Jul;94(7):658-68. Review. French.


Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE).

Blay JY, Koscielny S, Trédaniel J, Asselain B, Goldwasser F, Misset JL, de Labareyre C, Hagège C, Bismut H, Marty M.

Crit Rev Oncol Hematol. 2007 Nov;64(2):106-14. Epub 2007 Jul 30.


[Abdominal pain during the course of lung cancer].

Ba O, Almeida F, Fondronnier C, Michalski M, Gossot D, Savinelli F, Le Maignan C, Misset JL, Trédaniel J.

Rev Pneumol Clin. 2007 Apr;63(2):100-3. French.


Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PLoS Med. 2007 Mar;4(3):e90.


Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.

Caruba T, Cottu PH, Madelaine-Chambrin I, Espié M, Misset JL, Gross-Goupil M.

Breast J. 2007 Mar-Apr;13(2):165-71.


A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.

Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Misset JL.

Br J Cancer. 2006 Jun 5;94(11):1610-4.


[The consequences of passive smoking in adults].

Trédaniel J, Savinelli F, Vignot S, Bousquet G, Le Maignan C, Misset JL.

Rev Mal Respir. 2006 Apr;23 Suppl 2:4S67-4S73. Review. French.


A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, MacDonald JR, Misset JL, Cvitkovic E.

Invest New Drugs. 2006 Jul;24(4):311-9.


Current issues in adjuvant treatment of stage II colon cancer.

André T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A.

Ann Surg Oncol. 2006 Jun;13(6):887-98. Epub 2006 Apr 14. Review.


Follicular dendritic cell tumor of the mediastinum: expression of fractalkine and SDF-1alpha as mast cell chemoattractants.

Guettier C, Validire P, Emilie D, Tricottet V, Sebagh M, Anjo A, Misset JL, Reynes M.

Virchows Arch. 2006 Feb;448(2):218-22. Epub 2006 Jan 12.


Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.

Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Moluçon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P.

Ann Oncol. 2006 Mar;17(3):409-14. Epub 2005 Dec 6.


[Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].

Bugat R, Guastalla JP, Misset JL.

Bull Cancer. 2005 Nov;92(11):1003-6. French. No abstract available.


Prospective, double-blind, randomized trial of equimolar mixture of nitrous oxide/oxygen to prevent pain induced by insertion of venous access ports in cancer patients.

Douard MC, di Palma M, d'Agostino P, Chevret S, Kriegel I, Falissard B, Thierry P, George B, Bussières L, Misset JL.

Support Care Cancer. 2006 Feb;14(2):161-6. Epub 2005 Aug 11.


Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer.

Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espié M, Clot P, Servant JM, Misset JL, Marty M, Janin A.

Oncol Rep. 2005 Aug;14(2):513-20.


Decision making process in oncology practice: is the information available and what should it consist of?

Trédaniel J, Blay JY, Goldwasser F, Asselain B, Koscielny S, de Labareyre C, Balogh N, Bismut H, Misset JL, Marty M.

Crit Rev Oncol Hematol. 2005 Jun;54(3):165-70.


Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.

Raymond E, Kahatt C, Rigolet MH, Sutherland W, Lokiec F, Alexandre J, Tombal B, Elman M, Lee MS, MacDonald JR, Cullen M, Misset JL, Cvitkovic E.

Clin Cancer Res. 2004 Nov 15;10(22):7566-74. Erratum in: Clin Cancer Res. 2005 Feb 15;11(4):1684.


[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)].

Lhommé C, Ray-Coquard I, Guastalla JP, Bataillard A, Thomas L, Bonnier P, Dargent D, Dohollou N, Ganem G, Lefranc JP, Misset JL, Rixe O, Tchiknavorian X, Tournigand C, Villet R, Bachelot T, Kerbrat P, Fervers B, Basuyau JP, Cohen-Solal-Le Nir C, Morice P, Duvillard P, Voog E; Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC); Fédération Hospitalière de France (FHF); Fédération Nationale de Cancérologie des Centres Hospitaliers Régionaux Universitaires (FNCCHRU); Fédération Française de Cancérologie des Centres Hospitaliers Généraux (FFCCHG); Centres Régionaux de Lutte Contre le Cancer (CRLCC); Société Française d'Oncologie Gynécologique (SFOG).

Bull Cancer. 2004 Jul-Aug;91(7-8):609-20. French.


Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.

Misset JL, Gamelin E, Campone M, Delaloge S, Latz JE, Bozec L, Fumoleau P.

Ann Oncol. 2004 Jul;15(7):1123-9.


Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.

Alexandre J, Raymond E, Kaci MO, Brain EC, Lokiec F, Kahatt C, Faivre S, Yovine A, Goldwasser F, Smith SL, MacDonald JR, Misset JL, Cvitkovic E.

Clin Cancer Res. 2004 May 15;10(10):3377-85.


[Does primary chemotherapy really increase the rate of breast conserving treatments?].

Hennequin C, Espié M, Misset JL, Maylin C.

Cancer Radiother. 2004 Feb;8(1):48-53. Review. French.


Supplemental Content

Loading ...
Support Center